BridgeMD
New treatment option for Semaglutide-Induced Gastric Motility
Official title Effect of Itopride on Semaglutide Gastroparesis
ClinicalTrials.gov ID: NCT07254715
What this study is testing
What is Itopride HCI 50 mg?
Itopride HCI 50 mg is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for semaglutide-induced gastric motility.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Semaglutide delays gastric emptying and increases the risk of aspiration with anesthesia; So, the addition of prokinetics as Itopride, could enhance gastric emptying and hasten surgery. The investigator will evaluate the effect of Itopride on Semaglutide-induced gastroparesis and residual gastric contents after 8 hours of fasting by gastric ultrasound before anesthesia.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 60, women only
You may be able to join if
- American Society of Anesthesiologists grade I- III.
- Age: 40-60 years.
- BMI: 20-30 kg/m2.
- Diabetic patients on semaglutide (0.5-1mg) SC weekly.
- Undergoing elective hysterectomy.
You likely can't join if
- Declining to give written informed consent.
- history of upper abdominal surgery or the presence of hiatal hernia.
- Other medications inducing gastroparesis (opioids, proton pump inhibitors, tricyclic antidepressants, calcium channel blockers, antipsychotic...
- History of allergy to Itopride.
- History of cardiac arrhythmia or abnormal ECG.
- Neurologic diseases (including Parkinson's disease and multiple sclerosis)
See the full eligibility criteria
- American Society of Anesthesiologists grade I- III.
- Age: 40-60 years.
- BMI: 20-30 kg/m2.
- Diabetic patients on semaglutide (0.5-1mg) SC weekly.
- Undergoing elective hysterectomy.
- Declining to give written informed consent.
- history of upper abdominal surgery or the presence of hiatal hernia.
- Other medications inducing gastroparesis (opioids, proton pump inhibitors, tricyclic antidepressants, calcium channel blockers, antipsychotic medications, and lithium).
- History of allergy to Itopride.
- History of cardiac arrhythmia or abnormal ECG.
- Neurologic diseases (including Parkinson's disease and multiple sclerosis)
- Hepatic or renal failure.
The study team makes the final eligibility decision.
Where it's taking place
- Cairo, Cairo Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 40 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cairo, Cairo Governorate, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.